{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:27:26Z","timestamp":1791156446744,"version":"4.1.0"},"reference-count":53,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,12,4]]},"abstract":"<jats:p>Immune thrombocytopenia (ITP) comprises a heterogeneous group of disorders characterized by autoimmune-mediated platelet destruction and impairment of thrombopoiesis. ITP may occur in the absence of an evident predisposing etiology (primary ITP) or secondary to a growing list of associated conditions (secondary ITP), and must be differentiated from other causes of thrombocytopenia. This review focuses on primary ITP in adults. The traditional goal of therapy in this population is to achieve a hemostatic platelet count of 30 \u00d7 109\/L or above for most patients while minimizing treatment-related morbidity. This approach has been called into question by the recent advent of well-tolerated and effective agents for the management of ITP, including pulse-dose dexamethasone, rituximab, and the thrombopoietin receptor agonists. Recent studies suggest the potential for aggressive therapy at the time of diagnosis to alter the natural history of ITP and point to the importance of quality-of-life considerations in therapeutic decision making.<\/jats:p>","DOI":"10.1182\/asheducation-2010.1.377","type":"journal-article","created":{"date-parts":[[2011,1,16]],"date-time":"2011-01-16T19:08:48Z","timestamp":1295204928000},"page":"377-384","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":44,"title":["Immune Thrombocytopenia"],"prefix":"10.1182","volume":"2010","author":[{"given":"Adam","family":"Cuker","sequence":"first","affiliation":[{"name":"Departments of Medicine and of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Cines","sequence":"additional","affiliation":[{"name":"Departments of Medicine and of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111708505046500_B1","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1182\/blood-2009-01-129155","article-title":"The ITP syndrome: pathogenic and clinical diversity","volume":"113","author":"Cines","year":"2009","journal-title":"Blood"},{"key":"2019111708505046500_B2","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"2019111708505046500_B3","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan","year":"2010","journal-title":"Blood"},{"key":"2019111708505046500_B4","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1371\/journal.pmed.0030024","article-title":"Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia","volume":"3","author":"Stasi","year":"2006","journal-title":"PLoS Med"},{"key":"2019111708505046500_B5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2009.07615.x","article-title":"Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database","volume":"145","author":"Marieke Schoonen","year":"2009","journal-title":"Br J Haematol"},{"key":"2019111708505046500_B6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1600-0609.2009.01247.x","article-title":"The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review","volume":"83","author":"Abrahamson","year":"2009","journal-title":"Eur J Haematol"},{"key":"2019111708505046500_B7","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/j.1538-7836.2006.02147.x","article-title":"Prevalence of immune thrombocytopenia: analyses of administrative data","volume":"4","author":"Segal","year":"2006","journal-title":"J Thromb Haemost"},{"key":"2019111708505046500_B8","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/pbc.21005","article-title":"Idiopathic thrombocytopenic purpura (ITP): is there a genetic predisposition?","volume":"47","author":"Rischewski","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"2019111708505046500_B9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/tmrv.2003.50004","article-title":"Cellular immune mechanisms in autoimmune thrombocytopenic purpura: An update","volume":"17","author":"Coopamah","year":"2003","journal-title":"Transfus Med Rev"},{"key":"2019111708505046500_B10","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2008-01-135335","article-title":"Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura","volume":"112","author":"Yu","year":"2008","journal-title":"Blood"},{"key":"2019111708505046500_B11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2141.2006.06431.x","article-title":"High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura","volume":"136","author":"Emmerich","year":"2007","journal-title":"Br J Haematol"},{"key":"2019111708505046500_B12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1182\/blood-2009-06-228015","article-title":"Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins","volume":"115","author":"Craig","year":"2010","journal-title":"Blood"},{"key":"2019111708505046500_B13","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2005-01-0243","article-title":"Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia","volume":"106","author":"Li","year":"2005","journal-title":"Blood"},{"key":"2019111708505046500_B14","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1182\/blood-2008-09-181073","article-title":"Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia","volume":"113","author":"Zhang","year":"2009","journal-title":"Blood"},{"key":"2019111708505046500_B15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1365-2141.2003.04735.x","article-title":"Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura","volume":"124","author":"Takahashi","year":"2004","journal-title":"Br J Hematol"},{"key":"2019111708505046500_B16","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2008-07-167155","article-title":"Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review","volume":"113","author":"Stasi","year":"2009","journal-title":"Blood"},{"key":"2019111708505046500_B17","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJM199212173272503","article-title":"Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection","volume":"327","author":"Ballem","year":"1992","journal-title":"N Engl J Med"},{"key":"2019111708505046500_B18","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2003-01-0275","article-title":"Ultrastructural study shows morphological features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura","volume":"103","author":"Houwerzijl","year":"2003","journal-title":"Blood"},{"key":"2019111708505046500_B19","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1182\/blood-2003-08-2672","article-title":"Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP","volume":"103","author":"McMillan","year":"2004","journal-title":"Blood"},{"key":"2019111708505046500_B20","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2008-02-139402","article-title":"Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1","volume":"112","author":"Olsson","year":"2008","journal-title":"Blood"},{"key":"2019111708505046500_B21","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","article-title":"Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial","volume":"373","author":"Bussel","year":"2009","journal-title":"Lancet"},{"key":"2019111708505046500_B22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"key":"2019111708505046500_B23","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood-2008-04-150078","article-title":"Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP","volume":"113","author":"Bussel","year":"2009","journal-title":"Blood"},{"key":"2019111708505046500_B24","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0092-8674(01)00477-9","article-title":"Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia","volume":"106","author":"Nardi","year":"2001","journal-title":"Cell"},{"key":"2019111708505046500_B25","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/nm921","article-title":"T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura","volume":"9","author":"Olsson","year":"2003","journal-title":"Nat Med"},{"key":"2019111708505046500_B26","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminhematol.2008.12.005","article-title":"Pathobiology of secondary immune thrombocytopenia","volume":"46","author":"Cines","year":"2009","journal-title":"Semin Hematol"},{"key":"2019111708505046500_B27","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/blood.V99.6.1922","article-title":"Does treatment with intermittent infusions of inravenus anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenia to avoid splenectomy?","volume":"99","author":"Cooper","year":"2002","journal-title":"Blood"},{"key":"2019111708505046500_B28","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1182\/blood-2003-11-3908","article-title":"Long-term outcomes in adults with chronic ITP after splenectomy failure","volume":"104","author":"McMillan","year":"2004","journal-title":"Blood"},{"key":"2019111708505046500_B29","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2004-12-4598","article-title":"How I treat idiopathic thrombocytopenic purpura (ITP)","volume":"106","author":"Cines","year":"2005","journal-title":"Blood"},{"key":"2019111708505046500_B30","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1182\/blood-2006-09-044388","article-title":"Mapping helper T-cell epitopes on platelet membrane glycoprotein IIIa in chronic autoimmune thrombocytopenic purpura","volume":"109","author":"Sukati","year":"2007","journal-title":"Blood"},{"key":"2019111708505046500_B31","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/blood-2009-07-229815","article-title":"Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia","volume":"115","author":"Zaja","year":"2010","journal-title":"Blood"},{"key":"2019111708505046500_B32","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2141.2008.07464.x","article-title":"Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials","volume":"144","author":"George","year":"2009","journal-title":"Br J Haematol"},{"key":"2019111708505046500_B33","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ajh.20992","article-title":"Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura","volume":"83","author":"McMillan","year":"2008","journal-title":"Am J Hematol"},{"key":"2019111708505046500_B34","first-page":"1532","article-title":"A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP)","volume":"106","author":"Tarantino","year":"2005","journal-title":"Blood"},{"key":"2019111708505046500_B35","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1056\/NEJMoa030254","article-title":"Initial treatment of immune thrombocyopenic purpura with high-dose dexamethasone","volume":"349","author":"Cheng","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111708505046500_B36","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1182\/blood-2005-12-015222","article-title":"Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience","volume":"109","author":"Mazzucconi","year":"2007","journal-title":"Blood"},{"key":"2019111708505046500_B37","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1182\/blood-2007-01-065763","article-title":"Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP)","volume":"110","author":"Boruchov","year":"2007","journal-title":"Blood"},{"key":"2019111708505046500_B38","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1182\/blood-2004-03-1168","article-title":"Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications","volume":"104","author":"Kojouri","year":"2004","journal-title":"Blood"},{"issue":"4","key":"2019111708505046500_B39","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1182\/blood-2003-11-3908","article-title":"Long-term outcomes in adults with chronic ITP after splenectomy failure","volume":"104","author":"McMillan","year":"2004","journal-title":"Blood"},{"key":"2019111708505046500_B40","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1182\/blood-2009-04-210112","article-title":"Vascular complications after splenectomy for hematologic disorders","volume":"114","author":"Crary","year":"2009","journal-title":"Blood"},{"key":"2019111708505046500_B41","doi-asserted-by":"crossref","first-page":"440","DOI":"10.7861\/clinmedicine.2-5-440","article-title":"Update of guidelines for the prevention and treatment of infections in patients with an absent or dysfunctional spleen","volume":"2","author":"Davies","year":"2002","journal-title":"Clin Med"},{"key":"2019111708505046500_B42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146","author":"Arnold","year":"2007","journal-title":"Ann Intern Med"},{"key":"2019111708505046500_B43","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood-2008-01-131029","article-title":"Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study","volume":"112","author":"Godeau","year":"2008","journal-title":"Blood"},{"key":"2019111708505046500_B44","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3324\/haematol.12206","article-title":"Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura","volume":"93","author":"Zaja","year":"2008","journal-title":"Haematologica"},{"key":"2019111708505046500_B45","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"2019111708505046500_B46","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1182\/blood.V112.11.400.400","article-title":"Oral eltrombopag for the long-term treatment of patients with chronic idiopathic thrombocytopenic purpura: results of a phase III, double-blind, placebo-controlled study (RAISE) [Abstract]","volume":"112","author":"Cheng","year":"2008","journal-title":"Blood"},{"key":"2019111708505046500_B47","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1182\/blood.V114.22.682.682","article-title":"Long-term treatment of chronic immune thrombocytopenic purpura with oral eltrombopag: Results from the EXTEND study [Abstract]","volume":"114","author":"Saleh","year":"2009","journal-title":"Blood"},{"key":"2019111708505046500_B48","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/157488610790936196","article-title":"Safety of the thrombopoiesis-stimulating agents for the treatment of immune thrombocytopenia","volume":"5","author":"Cuker","year":"2010","journal-title":"Curr Drug Saf"},{"key":"2019111708505046500_B49","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3415.3415","article-title":"Long-term safety profile of romiplostim in patients with chronic immune thrombocytopenia (ITP)","volume":"112","author":"Liebman","year":"2008","journal-title":"Blood"},{"key":"2019111708505046500_B50","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood.V114.22.2423.2423","article-title":"Thromboembolic events observed in eltrombopag clinical trials in chronic immune thrombocytopenic purpura [Abstract]","volume":"114","author":"Bussel","year":"2009","journal-title":"Blood"},{"key":"2019111708505046500_B51","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ajh.20104","article-title":"Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies","volume":"76","author":"Aledort","year":"2004","journal-title":"Am J Hematol"},{"key":"2019111708505046500_B52","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1053\/j.seminhematol.2010.03.002","article-title":"Toxicities of the thrombopoietic growth factors","volume":"47","author":"Cuker","year":"2010","journal-title":"Semin Hematol"},{"key":"2019111708505046500_B53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2009-06-222448","article-title":"Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura","volume":"115","author":"Arnold","year":"2010","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2010\/1\/377\/319901\/bep00110000377.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2010\/1\/377\/319901\/bep00110000377.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T18:04:48Z","timestamp":1592244288000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2010\/1\/377\/96297\/Immune-Thrombocytopenia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,4]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2010.1.377","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,4]]}}}